ライフサイエンスコーパス: cell transplantation

1 are potential candidates for autologous stem cell transplantation.

2 tion for patients undergoing allogeneic stem cell transplantation.

3 et in patients undergoing hematopoietic stem cell transplantation.

4 to intensive strategies with autologous stem cell transplantation.

5 Seven patients underwent hematopoietic stem cell transplantation.

6 al late effects following hematopoietic stem cell transplantation.

7 chievable with allogeneic hematopoietic stem cell transplantation.

8 ncer and those undergoing hematopoietic stem-cell transplantation.

9 elapsed at </=12 months from autologous stem cell transplantation.

10 ications for HIV cure regimens based on stem cell transplantation.

11 sfusion in the setting of hematopoietic stem-cell transplantation.

12 us-host disease (GVHD) after allogeneic stem-cell transplantation.

13 betes, and also reduces the success of islet cell transplantation.

14 sion and allow subsequent hematopoietic stem cell transplantation.

15 e in both solid organ and hematopoietic stem cell transplantation.

16 tion following allogeneic hematopoietic stem cell transplantation.

17 ediatric patients undergoing allogeneic stem-cell transplantation.

18 lted only with allogeneic hematopoietic stem-cell transplantation.

19 ggered IBD and allogeneic hematopoietic stem cell transplantation.

20 ch treatment group underwent allogeneic stem-cell transplantation.

21 ear after treatment with haematopoietic stem cell transplantation.

22 who are eligible to receive autologous stem-cell transplantation.

23 21) days after allogeneic hematopoietic stem cell transplantation.

24 on to rapid relapse after hematopoietic stem cell transplantation.

25 who had received consecutive allogeneic stem-cell transplantation.

26 tients with acute GVHD after allogeneic stem-cell transplantation.

27 mitted to come off study for autologous stem cell transplantation.

28 ions are common following hematopoietic stem cell transplantation.

29 s homozygotes and also survived injury after cell transplantation.

30 whole-brain radiotherapy and autologous stem cell transplantation.

31 ty in the first year after haemopoietic stem cell transplantation.

32 mmonly used in solid organ and hematopoietic cell transplantation.

33 ast anti-lymphoma therapy, and previous stem-cell transplantation.

34 the HSC niche to optimize hematopoietic stem cell transplantation.

35 elopment within 1 year of hematopoietic stem cell transplantation.

36 ient technique to prepare the host liver for cell transplantation.

37 7%) undergoing autologous hematopoietic stem cell transplantation.

38 isease (GVHD) after allogeneic hematopoietic cell transplantation.

39 ), a relatively new technique of limbal stem cell transplantation.

40 e to the success of allogeneic hematopoietic cell transplantation.

41 sus-host interaction following hematopoietic cell transplantation.

42 ents underwent allogeneic hematopoietic stem cell transplantation.

43 ls (HSCs) during an allogeneic hematopoietic cell transplantation.

44 serve intensive salvage with autologous stem cell transplantation.

45 mia (AML) following allogeneic hematopoietic cell transplantation.

46 ions: Unrelated donor BM or PB hematopoietic cell transplantation.

47 10.5-124 d) in autologous hematopoietic stem cell transplantation.

48 motherapy with or without hematopoietic stem cell transplantation.

49 nd mortality from GVHD after allogeneic stem cell transplantation.

50 ly infected cells before haematopoietic stem cell transplantation.

51 lammatory loss of graft function after islet cell transplantation.

52 and mortality after allogeneic hematopoietic cell transplantation.

53 tive option for CMML remains allogeneic stem cell transplantation.

54 outcomes after allogeneic hematopoietic stem-cell transplantation.

55 t alternative to improve the outcome of stem cell transplantation.

56 s a major complication of hematopoietic stem cell transplantation.

57 earlier relapse, respectively, received stem cell transplantations.

58 to undergo observation after autologous stem-cell transplantation (120 patients per group); 59 patien

59 %), alkylating agents (91%), autologous stem cell transplantation (78%), thalidomide (44%), and lenal

60 The success of allogeneic hematopoietic stem cell transplantation, a key treatment for many disorders

61 During hematopoietic stem cell transplantation, a substantial number of donor cell

62 In hematopoietic stem cell transplantation, acute graft-versus-host-disease (G

63 mmatory microenvironment in combination with cell transplantation after SCI.SIGNIFICANCE STATEMENT Th

64 s-host-disease (cGVHD) after allogeneic stem cell transplantation (AHSCT) may resemble autoimmune dis

65 ymphomas after allogeneic hematopoietic stem cell transplantation (AHSCT), but can also damage health

66 of mortality after allogeneic hematopoietic-cell transplantation (allo-HCT) are relapse, graft-versu

67 e (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT) by suppressing conventio

68 Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curativ

69 Allogeneic hematopoietic cell transplantation (allo-HCT) is indicated for patient

70 botulism in an allogeneic hematopoietic stem cell transplantation (allo-HCT) recipient.

71 ing complication of allogeneic hematopoietic cell transplantation (allo-HCT).

72 ain complication of allogeneic hematopoietic cell transplantation (allo-HCT).

73 se (GVHD) following allogeneic hematopoietic cell transplantation (allo-HCT).

74 lly treated by allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in childhood.

75 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curati

76 recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT), who receive intensive

77 ortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

78 tigated during allogeneic hematopoietic stem cell transplantation (allo-HSCT).

79 case of HIV-1 cure following allogeneic stem cell transplantation (allo-SCT), several subsequent case

80 ortality and morbidity after allogeneic stem cell transplantation (allo-SCT).

81 orbidity and mortality after allogeneic stem cell transplantation (allo-SCT).

82 GVL) effect in allogeneic hematopoietic stem cell transplantation (alloSCT) is potent against chronic

83 15.1-139 d) in allogeneic hematopoietic stem cell transplantation and 14.2 days (interquartile range,

84 6%) undergoing allogeneic hematopoietic stem cell transplantation and 58 patients (2.7%) undergoing a

85 mphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin.

86 omplication of allogeneic hematopoietic stem cell transplantation and causes disabling systemic infla

87 ediatric patients undergoing autologous stem-cell transplantation and for adult and pediatric patient

88 stressful conditions, such as hematopoietic cell transplantation and G-CSF- or inflammation-induced

89 Trials of hematopoietic stem cell transplantation and gene therapy for primary immuno

90 r definitive therapy with hematopoietic stem cell transplantation and gene therapy.

91 wn from the study to undergo allogeneic stem-cell transplantation and later died from transplantation

92 rior platelet recovery after cord blood stem cell transplantation and may underlie inefficient platel

93 sis, including allogeneic hematopoietic stem cell transplantation and multikinase inhibitors directed

94 t therapy, oral lipid-lowering therapy, stem-cell transplantation, and liver transplantation.

95 Furthermore, we took a hematopoietic stem cell transplantation approach to generating a SCD model

96 nal studies and referral for allogeneic stem cell transplantation are also discussed.

97 The results of hematopoietic cell transplantation are analyzed, and recommendations m

98 Donors for allogeneic stem cell transplantation are preferentially matched with pat

99 ent BSCB repair processes, supporting hBM34+ cell transplantation as a future therapeutic strategy fo

100 high-dose chemotherapy with autologous stem-cell transplantation (ASCT) as first-line treatment in p

101 ed as a predictive factor of allogeneic stem cell transplantation (ASCT) benefit.

102 de maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progr

103 that in patients undergoing autologous stem-cell transplantation (ASCT) for lymphoma, CHIP at the ti

104 as induction therapy before autologous stem-cell transplantation (ASCT) in patients with relapsed or

105 oma (DLBCL) not eligible for autologous stem cell transplantation (ASCT) or having relapse after ASCT

106 up-front consolidation with autologous stem cell transplantation (ASCT) remain controversial issues

107 idomide versus placebo after autologous stem-cell transplantation (ASCT) was investigated for patient

108 lle score </=2) proceeded to autologous stem cell transplantation (ASCT) whereas PET-positive patient

109 ve chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alternative to whole-

110 nd patients could proceed to autologous stem cell transplantation (ASCT).

111 that predict outcomes after autologous stem-cell transplantation (ASCT).

112 /ref) DEL or DHL who undergo autologous stem-cell transplantation (ASCT).

113 ssion and deletion studies, including single-cell transplantation assays, revealed that Mfn2 is speci

114 pts and behave differently than neoblasts in cell transplantation assays.

115 , adult patients who undergo autologous stem-cell transplantation at experienced centers may receive

116 th DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce the risk of rel

117 who received an allogeneic haemopoietic stem cell transplantation between Jan 1, 2007, and Feb 28, 20

118 MM and underwent autologous bone marrow stem cell transplantation (BMT) were evaluated.

119 ation after allogeneic bone marrow nucleated cell transplantation but also exhibited improved capacit

120 4.7 T at days 1, 3, 7, 14, 21, and 28 after cell transplantation by using a gradient-echo sequence w

121 In addition, cell transplantation carries immunogenicity and/or tumou

122 chronic GVHD after allogeneic hematopoietic cell transplantation, characterized by fibrosis of skin

123 Allogeneic hematopoietic stem cell transplantation combines cytoreductive chemotherapy

124 already incorporated into the hematopoietic cell transplantation-comorbidity index (HCT-CI), were ev

125 nts undergoing allogeneic hematopoietic stem cell transplantation continue to improve, but chronic gr

126 Previous studies have indicated that stem-cell transplantation could be an effective treatment.

127 tes an adaptive immune memory response, stem cell transplantation disrupts this learned immunity.

128 stress syndrome following hematopoietic stem cell transplantation do not meet criteria for a more spe

129 ed early after allogeneic hematopoietic stem cell transplantation do not support the use of extracorp

130 nt complication following hematopoietic stem cell transplantation, dramatically influencing patient-i

131 donor CD4+ T cells early after hematopoietic cell transplantation effectively prevents GVHD while pre

132 wn about neutrophil activity over time after cell transplantation, especially regarding A fumigatus.

133 ions, donor selection for hematopoietic stem cell transplantation, evaluation of comorbidities, and s

134 ry immunodeficiency disease registries, stem cell transplantation facilities, and neonatal screening

135 0 patients) or high-dose melphalan plus stem-cell transplantation followed by two additional cycles o

136 hasone (RVD) with or without autologous stem-cell transplantation, followed by lenalidomide maintenan

137 additional chemotherapy and autologous stem cell transplantation for bone marrow rescue.

138 pheral blood (PB) (N = 551) in hematopoietic cell transplantation for hematologic neoplasms.

139 nts undergoing allogeneic hematopoietic stem-cell transplantation for MDS may inform prognostic strat

140 y treated with allogeneic hematopoietic stem cell transplantation for more than 4 decades.

141 Over the past years, stem cell transplantation for repair of the CNS has received

142 rtium describe the outcomes of hematopoietic cell transplantation for SCID during 2000-2009, diagnost

143 c chemotherapy or subsequent autologous stem cell transplantation for treatment of hematological mali

144 a who received allogeneic hematopoietic stem cell transplantation from a homozygous CCR5 Delta32 dono

145 halted after allogeneic haematopoietic stem cell transplantation from a related donor.

146 highlight the utility for hematopoietic stem cell transplantation, frozen samples of cord blood were

147 to 73.2%; P = 0.33) and that allogeneic stem-cell transplantation had a beneficial effect in a large

148 e and two who had received haemopoietic stem cell transplantation had either no response or were not

149 ertoires at 9-12 mo after hematopoietic stem cell transplantation had increased disease-free survival

150 erapy is inefficient, and hematopoietic stem cell transplantation has a poor prognosis.

151 Allogeneic haematopoietic stem cell transplantation has been demonstrated to provide lo

152 High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for

153 Islet cell transplantation has limited effectiveness because o

154 Allogeneic stem cell transplantation has the possibility for cure becaus

155 refractory or relapsed after autologous stem-cell transplantation have a grim prognosis, and new trea

156 c patients undergoing sequential LT and stem cell transplantation have been described in the literatu

157 sDNA) viruses after allogeneic hematopoietic cell transplantation (HCT) are limited by incomplete und

158 iral reactivations (VRs) after hematopoietic cell transplantation (HCT) contribute to significant mor

159 major cause of allogeneic hematopoietic stem cell transplantation (HCT) failure, and the prognosis fo

160 tients treated with allogeneic hematopoietic cell transplantation (HCT) from 2010 to 2014, including

161 HD) is higher after allogeneic hematopoietic cell transplantation (HCT) from unrelated donors as comp

162 Hematopoietic cell transplantation (HCT) has been considered a curativ

163 Hematopoietic cell transplantation (HCT) has now been shown to be safe

164 tments and complications after hematopoietic cell transplantation (HCT) injure normal tissues and may

165 Hematopoietic cell transplantation (HCT) is a critical treatment of pa

166 Hematopoietic cell transplantation (HCT) is curative for FA-related ma

167 its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known.

168 en intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown.

169 ter matched-related allogeneic hematopoietic cell transplantation (HCT) recently showed no difference

170 Allogeneic hematopoietic cell transplantation (HCT) represents a potentially cura

171 serious health outcomes among hematopoietic cell transplantation (HCT) survivors versus a matched po

172 ablative HLA-matched unrelated hematopoietic cell transplantation (HCT) were randomly assigned one to

173 (HSC) homing is important for hematopoietic cell transplantation (HCT), especially when HSC numbers

174 uring hospitalization for hematopoietic stem cell transplantation (HCT), patients receive high-dose c

175 After hematopoietic cell transplantation (HCT), polyoma-BK virus is associat

176 When considering HLA-matched hematopoietic cell transplantation (HCT), sibling and unrelated donors

177 c malignancies cannot tolerate hematopoietic cell transplantation (HCT), whereas others may not have

178 h children required allogeneic hematopoietic cell transplantation (HCT), which resolved their autoimm

179 ty conditioning, related donor hematopoietic cell transplantation (HCT).

180 atients who undergo allogeneic hematopoietic cell transplantation (HCT).

181 after myeloablative allogeneic hematopoietic cell transplantation (HCT).

182 mortality following allogeneic hematopoietic cell transplantation (HCT).

183 hreatening complications after hematopoietic cell transplantation (HCT).

184 roves outcomes after allogeneic haemopoietic cell transplantation (HCT).

185 HD) is common after allogeneic hematopoietic cell transplantation (HCT).

186 ) occurs frequently after hematopoietic stem cell transplantation (HSCT) and can lead to significant

187 me dynamics in allogeneic hematopoietic stem cell transplantation (HSCT) and enteric graft-versus-hos

188 Autologous hematopoietic stem cell transplantation (HSCT) and mesenchymal stromal cell

189 em cells to use in early haematopoietic stem cell transplantation (HSCT) approaches for several genet

190 ions following allogeneic hematopoietic stem cell transplantation (HSCT) are a major cause of morbidi

191 complications (NC) after hematopoietic stem cell transplantation (HSCT) are rare events.

192 ecognized complication of hematopoietic stem cell transplantation (HSCT) associated with excessive co

193 ilisation and autologous haematopoietic stem-cell transplantation (HSCT) compared with mobilisation f

194 T-cell immunity following hematopoietic stem cell transplantation (HSCT) could assist clinicians in m

195 Hematopoietic stem cell transplantation (HSCT) cures the T-lymphocyte, B-ly

196 Haemopoietic stem-cell transplantation (HSCT) eradicates host haemopoiesis

197 s improved survival after hematopoietic stem cell transplantation (HSCT) for hemophagocytic lymphohis

198 Allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA-haploidentical r

199 patients after allogeneic hematopoietic stem cell transplantation (HSCT) has not been prospectively s

200 mendations for allogeneic hematopoietic stem cell transplantation (HSCT) in myelodysplastic syndromes

201 ides a clear rationale for hematopoetic stem cell transplantation (HSCT) in patients with severe comb

202 Allogeneic hematopoietic stem cell transplantation (HSCT) is a critically important th

203 Hematopoietic stem cell transplantation (HSCT) is an important therapy for

204 Allogeneic hematopoietic stem cell transplantation (HSCT) is used as a therapeutic app

205 Autologous hematopoietic stem cell transplantation (HSCT) of gene-modified cells is an

206 Hematopoietic stem cell transplantation (HSCT) offers curative therapy for

207 Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only treatment o

208 Hematopoietic stem cell transplantation (HSCT) represents a potential defin

209 olerance after allogeneic hematopoietic stem cell transplantation (HSCT) requires the balanced recons

210 The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) was monitored.

211 s treated with allogeneic hematopoietic stem-cell transplantation (HSCT) will require efforts to decr

212 lutionized haploidentical hematopoietic stem cell transplantation (HSCT), allowing safe infusion of u

213 f illness and death after hematopoietic stem cell transplantation (HSCT), and updated epidemiological

214 emotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), at least in younger patient

215 r limitation of allogeneic haemopoietic stem-cell transplantation (HSCT), for which no approved treat

216 omplication of allogeneic hematopoietic stem cell transplantation (HSCT), posing as a significant bar

217 r treatment and subsequent haemopoietic stem-cell transplantation (HSCT).

218 patients after allogeneic hematopoietic stem cell transplantation (HSCT).

219 failure after allogeneic hematopoietic stem cell transplantation (HSCT).

220 nt a sequential liver and hematopoietic stem cell transplantation (HSCT).

221 en in patients undergoing hematopoietic stem cell transplantation (HSCT).

222 d favorable outcome after hematopoietic stem cell transplantation (HSCT).

223 ution postirradiation and hematopoietic stem cell transplantation (HSCT).

224 reatening complication of hematopoietic stem cell transplantation (HSCT).

225 omplication of allogeneic hematopoietic stem cell transplantation (HSCT).

226 ulation, especially after hematopoietic stem cell transplantation (HSCT).

227 by this case, we studied the impact of stem cell transplantation in a macaque simian/HIV (SHIV) syst

228 al benefit of allogeneic haematopoietic stem cell transplantation in adult cerebral adrenoleukodystro

229 and effective alternative to allogeneic stem-cell transplantation in boys with early-stage cerebral a

230 key role post allogeneic hematopoietic stem cell transplantation in the generation of a broad but se

231 hen assessed the effectiveness of murine UCB cells transplantation in busulfan-conditioned newborn MP

232 ntal approaches including bar coding, single cell transplantation, in vivo lineage tracing, and HSC-s

233 Specific complications during stem cell transplantation included deterioration of motor and

234 ) proceeded to allogeneic hematopoietic stem-cell transplantation, including 55% (six of 11) of trans

235 be cured when allogeneic hematopoietic stem-cell transplantation induces a graft-versus-leukemia imm

236 Hematopoietic stem cell transplantation is a potential curative therapy for

237 o successful use of allogeneic hematopoietic cell transplantation is acute graft-versus-host disease

238 Allogeneic hematopoietic stem cell transplantation is hampered by chronic graft-versus

239 ffected patients for whom hematopoietic stem cell transplantation is not available.

240 Hematopoietic stem cell transplantation is the standard treatment; however,

241 Stem cell transplantation is used to treat these diseases, bu

242 Hematopoietic cell transplantation is, to date, the only curative ther

243 In utero hematopoietic cell transplantation (IUHCT) is a novel nonmyeloablative

244 in the liver, LT without hematopoietic stem cell transplantation leaves the new liver at risk for si

245 These results suggest that BM stem cell transplantation may be a promising therapy for AATD

246 a consolidation by means of autologous stem cell transplantation may offer a greater chance of long-

247 n followed by autologous haematopoietic stem cell transplantation, mesenchymal and related stem cell

248 sfusions and hydroxycarbamide, although stem cell transplantation might be a potentially curative the

249 ues asked whether the results of neural stem cell transplantation might be improved by accommodating

250 heroids and suggest that haematopoietic stem cell transplantation might have a therapeutic role for t

251 etoposide, and allogeneic hematopoietic stem cell transplantation; more than 50% of children who unde

252 mouse model in combination with bone marrow cell transplantation, MRI, and neurocognitive functional

253 lternative to AEDs, novel therapies based on cell transplantation offer an opportunity for long-lasti

254 Autologous stem cell transplantation offers a safe treatment platform, b

255 treated with allogeneic haematopoietic stem cell transplantation on a compassionate basis in four Eu

256 Hematopoietic stem cell transplantation or gene therapy offer a cure, but d

257 f 30 primary samples from hematopoietic stem cell transplantation patients with and without cGVHD.

258 munochemotherapy followed by autologous stem-cell transplantation, patients have relapses.

259 hemotherapy (HDCT) and peripheral-blood stem-cell transplantation (PBSCT) at Indiana University betwe

260 ransplantation, mesenchymal and related stem cell transplantation, pharmacologic manipulation of endo

261 an one lysosomal disorder (haemopoietic stem cell transplantation, pharmacological chaperones, substr

262 apsed lymphoma post-allogeneic hematopoietic cell transplantation (post-allo-HCT) and the success of

263 ary, long-term allogeneic hematopoietic stem cell transplantation recipients otherwise eligible for f

264 All allogeneic hematopoietic stem cell transplantation recipients treated with venovenous

265 children with cancer and hematopoietic stem-cell transplantation recipients.

266 en assessed in allogeneic hematopoietic stem cell transplantation recipients.

267 ponse, rate of allogeneic hematopoietic stem-cell transplantation, relapse-free survival, overall sur

268 layed transplantation.SIGNIFICANCE STATEMENT Cell transplantation represents a promising therapy for

269 (rs11465384 and rs7248637), allogeneic stem cell transplantation, respiratory virus infection, and A

270 l immune responses following allogeneic stem cell transplantation resulting in acute graft-versus-hos

271 Allogeneic stem cell transplantation (SCT) has been proposed as a therap

272 soring patients who received allogeneic stem cell transplantation (SCT) in first remission at SCT tim

273 Admission of allogeneic stem cell transplantation (SCT) recipients to the intensive c

274 and no identified donor for allogeneic stem-cell transplantation (SCT) were eligible.

275 points, and did not undergo allogeneic stem cell transplantation (SCT).

276 s a major complication after allogeneic stem cell transplantation (SCT).

277 Therefore, allogeneic hematopoietic stem cell transplantation should always be an initial conside

278 with chemosensitive disease, autologous stem cell transplantation should be considered at first or se

279 These findings open new avenues in cell transplantation strategies as they indicate success

280 disease after allogeneic hematopoietic stem cell transplantation, suggesting normal suppressive func

281 240 days after allogeneic hematopoietic stem cell transplantation survived compared to six of 13 (46%

282 enerative therapeutic strategy to substitute cell transplantation that could be beneficial for patien

283 ed KIR-HLA mismatching in hematopoietic stem cell transplantation therapy for leukemia and new, more

284 rt the development of future dopamine neuron cell transplantation therapy-based approaches, indicatin

285 dental pulp tissues, are potential tools for cell transplantation therapy.

286 d a future clinical strategy for HLA-matched cell transplantation to reduce immunological graft rejec

287 ay have implications on the efficacy of beta-cell transplantation treatments for type 1 diabetes.

288 ren shortly before and after allogeneic stem cell transplantation twice weekly by use of a commercial

289 2D signaling in unrelated hematopoietic stem cell transplantation (uHSCT).

290 t outcomes and optimal treatment (early stem cell transplantation vs long-term administration of tyro

291 .052) during the 6 months following MSC-NTF cell transplantation vs the pretreatment period.

292 Until recently, hematopoietic stem cell transplantation was the only curative option for Wi

293 ance after HLA 10/10 matched allogeneic stem cell transplantation, we show that in this matched setti

294 lication after allogeneic hematopoietic stem cell transplantation which causes high morbidity and mor

295 and was reduced following hematopoietic stem cell transplantation, which is the only therapy currentl

296 is a serious complication of allogeneic stem cell transplantation with few effective options availabl

297 These tools allow image-guided single cell transplantation with high spatial control.

298 loidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who re

299 uch as human islet or stem cell-derived beta cell transplantation) without immunosuppression.

300 hosphamide given after G-CSF-mobilized blood cell transplantation would reduce the cumulative 1-year